shares of neurobo pharmaceuticals inc more than tripled on tuesday surging for a second straight day after the clinicalstage biotechnology company unveiled a onefor30 reverse stock split neurobo announced the reverse split before the closing bell on monday and effected it after the close of a trading session that saw its share price double to 556 cents or around 1667 on a splitadjusted basis shares of the boston company moved lower in premarket trading tuesday after the split became effective but took flight when trading opened and were recently changing hands at 51 more than triple mondays splitadjusted closing price trading was paused several times due to volatility in its most recent quarterly report filed last month with the securities and exchange commission neurobo said it had enough cash to fund its operations into the first quarter of 2023 and that it will need to continue to raise a substantial amount of funds until it is able to generate sufficient revenues to fund its development activities the company also said that it had an accumulated deficit from its inception of 88 million as of june 30 and that there is substantial doubt about its ability to continue as a going concern